Structure Therapeutics (GPCR) Stock Price, News & Analysis

Company Overview

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development. These programs are directed at GPCR targets implicated in diseases such as nonalcoholic steatohepatitis (NASH), fibrosis and immune‐mediated inflammatory conditions. By applying structure‐guided optimization and high‐throughput screening, Structure Therapeutics aims to generate drug candidates with improved selectivity, potency and safety profiles compared with existing modalities.

Founded in 2018, the company initially operated under the name GPCR Therapeutics before rebranding as Structure Therapeutics in 2023 to reflect its emphasis on structure‐based drug design. Headquartered in Boston, Massachusetts, Structure Therapeutics collaborates with academic centers, contract research organizations and strategic partners to advance its research and development programs. Its integrated approach combines in silico modeling, biophysical assays and in vivo validation to streamline candidate progression toward human trials.

Led by a management team with extensive experience in drug discovery, translational research and clinical development, Structure Therapeutics aims to address areas of high unmet medical need. The company’s scientific leadership includes experts in GPCR biology, structural biology and pharmacology, positioning it to capitalize on breakthroughs in receptor structure elucidation and computational methods. Through its novel platform and focused pipeline, Structure Therapeutics seeks to bring first‐in‐class or best‐in‐class therapies to patients worldwide.

Key Stats

• Today's Range: $18.49 to $20.00
• 50-Day Range: $16.20 to $21.08
• 52-Week Range: $13.22 to $45.37
• Volume: 2.31 million shs
• Average Volume: 1.07 million shs
• Market Capitalization: $1.14 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $75.71
• Consensus Rating: Buy

Structure Therapeutics Stock Analysis - MarketRank™

Structure Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 641st out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Structure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Structure Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Structure Therapeutics are expected to grow in the coming year, from ($0.82) to ($0.62) per share.

Price to Book Value per Share Ratio

Structure Therapeutics has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.35% of the float of Structure Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Structure Therapeutics has a short interest ratio ("days to cover") of 8.8.

Change versus previous month

Short interest in Structure Therapeutics has recently increased by 0.97%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Structure Therapeutics does not currently pay a dividend.

Dividend Growth

Structure Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.35% of the float of Structure Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Structure Therapeutics has a short interest ratio ("days to cover") of 8.8.

Change versus previous month

Short interest in Structure Therapeutics has recently increased by 0.97%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.35

News Sentiment

Structure Therapeutics has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Structure Therapeutics this week, compared to 5 articles on an average week.

Search Interest

6 people have searched for GPCR on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Structure Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Structure Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.60% of the stock of Structure Therapeutics is held by insiders.

Percentage Held by Institutions

91.78% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GPCR Stock Analysis - Frequently Asked Questions

How have GPCR shares performed this year?

Structure Therapeutics' stock was trading at $27.12 on January 1st, 2025. Since then, GPCR stock has decreased by 27.1% and is now trading at $19.76.

How were Structure Therapeutics' earnings last quarter?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) posted its quarterly earnings results on Wednesday, August, 6th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.08.

When did Structure Therapeutics IPO?

Structure Therapeutics (GPCR) raised $150 million in an initial public offering on Friday, February 3rd 2023. The company issued 10,740,000 shares at a price of $13.00-$15.00 per share.

Who are Structure Therapeutics' major shareholders?

Structure Therapeutics' top institutional shareholders include Ameriprise Financial Inc. (2.76%), Vestal Point Capital LP (2.08%), Orbimed Advisors LLC (2.08%) and Franklin Resources Inc. (1.29%).

How do I buy shares of Structure Therapeutics?

Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Structure Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Structure Therapeutics investors own include Alamos Gold (AGI), Plug Power (PLUG), KALA BIO (KALA), Ovid Therapeutics (OVID), Comtech Telecommunications (CMTL), Fortress Biotech (FBIO) and Alto Ingredients (ALTO).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/04/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GPCR
• CIK: 1888886
• Web: www.structuretx.com
• Phone: 628-229-9277
• Fax: N/A
• Employees: 136
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Structure Therapeutics: $75.71
• High Price Target: $118.00
• Low Price Target: $50.00
• Potential Upside/Downside: +283.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$122.53 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -21.31%
• Return on Assets: -20.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.48
• Quick Ratio: 20.48

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.40 per share
• Price / Book: 1.47

Miscellaneous

• Outstanding Shares: 57,600,000
• Free Float: 54,373,000
• Market Cap: $1.14 billion
• Optionable: Optionable
• Beta: -1.88